AVXL Jan 2024 13.000 call
| Previous close | 4.9000 |
| Open | 5.5000 |
| Bid | 4.2000 |
| Ask | 7.1000 |
| Strike | 13.00 |
| Expiry date | 2024-01-19 |
| Day's range | 4.5000 - 5.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 77 |
- GlobeNewswire
Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022
Webcast and Conference Call To be Held Monday December 5, 2022, 8:30 am ETNEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that management will host
- Motley Fool
Why Anavex Life Sciences Stock Is Surging Today
The biotech reported positive results from a phase 2b/3 study of its lead Alzheimer's disease candidate.
- GlobeNewswire
ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease
Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADLKey Secondary Endpoint CDR-SB Also Met, Demonstrating Statistically Significant ResultsPlan to Meet with Regulatory Authorities to Determine Next Steps NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the trea
